Literature DB >> 24793442

An assessment by the Statin Cognitive Safety Task Force: 2014 update.

Carlos H Rojas-Fernandez1, Larry B Goldstein2, Allan I Levey3, Beth A Taylor4, Vera Bittner5.   

Abstract

The National Lipid Association's Safety Task Force convened a consensus conference of experts to develop a position statement on cognitive function to revise and update that published originally by the Association in the 2006 assessment of statin safety by a panel of neurologists. The current expert panel was charged with addressing the specific issue of potential adverse cognitive effects attributable to statins. Search strategies recently used in systematic reviews were used to identify relevant evidence using keywords and topics via Medline searches from 1966 to December 2013. Manual searches of bibliographies were also conducted. Panel members were asked to use the evidence to formulate answers to a series of questions of relevance to the subject matter. The strength of recommendations and quality of evidence were graded using accepted contemporary definitions and procedures. Recommendations to patients, health professionals, and researchers were put forth by the panel to aid in daily clinical decision making, and in future research endeavors.
Copyright © 2014 National Lipid Association. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Adverse drug effects; Cognition; Iatrogenesis; Memory; Statins

Mesh:

Substances:

Year:  2014        PMID: 24793442     DOI: 10.1016/j.jacl.2014.02.013

Source DB:  PubMed          Journal:  J Clin Lipidol        ISSN: 1876-4789            Impact factor:   4.766


  20 in total

Review 1.  Impact on cognitive function-are all statins the same?

Authors:  Nishant P Shah; Kristopher J Swiger; Seth S Martin
Journal:  Curr Atheroscler Rep       Date:  2015-01       Impact factor: 5.113

Review 2.  Non-traditional dosing of statins in statin-intolerant patients-is it worth a try?

Authors:  Marc-Andre Cornier; Robert H Eckel
Journal:  Curr Atheroscler Rep       Date:  2015       Impact factor: 5.113

Review 3.  Current drug treatment of hyperlipidemia in older adults.

Authors:  Dave L Dixon; Krista L Donohoe; Kelechi C Ogbonna; Sarah M Barden
Journal:  Drugs Aging       Date:  2015-02       Impact factor: 3.923

Review 4.  Statins and their effect on cognition: Let's clear up the confusion.

Authors:  Jérémie M Gauthier; Anne Massicotte
Journal:  Can Pharm J (Ott)       Date:  2015-05

Review 5.  Developmental and extrahepatic physiological functions of SREBP pathway genes in mice.

Authors:  Luke J Engelking; Mary Jo Cantoria; Yanchao Xu; Guosheng Liang
Journal:  Semin Cell Dev Biol       Date:  2017-07-20       Impact factor: 7.727

Review 6.  Evolocumab: Considerations for the Management of Hyperlipidemia.

Authors:  Barbara S Wiggins; Jeffrey Senfield; Helina Kassahun; Armando Lira; Ransi Somaratne
Journal:  Curr Atheroscler Rep       Date:  2018-03-06       Impact factor: 5.113

Review 7.  The pharmacodynamic and clinical trial evidence for statin dose.

Authors:  Simon B Dimmitt; Hans G Stampfer; John B Warren
Journal:  Br J Clin Pharmacol       Date:  2018-04-16       Impact factor: 4.335

8.  Design and rationale of the EBBINGHAUS trial: A phase 3, double-blind, placebo-controlled, multicenter study to assess the effect of evolocumab on cognitive function in patients with clinically evident cardiovascular disease and receiving statin background lipid-lowering therapy-A cognitive study of patients enrolled in the FOURIER trial.

Authors:  Robert P Giugliano; Francois Mach; Kenton Zavitz; Christopher Kurtz; Jingjing Schneider; Huei Wang; Anthony Keech; Terje R Pedersen; Marc S Sabatine; Peter S Sever; Narimon Honarpour; Scott M Wasserman; Brian R Ott
Journal:  Clin Cardiol       Date:  2017-02-16       Impact factor: 2.882

Review 9.  Approach to Statin Use in 2016: an Update.

Authors:  P Elliott Miller; Seth S Martin
Journal:  Curr Atheroscler Rep       Date:  2016-05       Impact factor: 5.113

Review 10.  Benefit-risk assessment of pitavastatin for the treatment of hypercholesterolemia in older patients.

Authors:  Kevin W Chamberlin; William L Baker
Journal:  Clin Interv Aging       Date:  2015-04-16       Impact factor: 4.458

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.